Results 61 to 70 of about 76,403 (315)

Listerin Alleviates Alzheimer's Disease through IRE1‐mediated Decay of TLR4 mRNA

Advanced Science, EarlyView.
Alzheimer's disease (AD) progression is influenced by microglia‐mediated neuroinflammation. Here, it is demonstrated that Listerin suppresses neuroinflammatory signaling and cognitive impairment in AD models by triggering IRE1α‐mediated TLR4 mRNA decay. Adenoviral Listerin delivery reduces amyloid‐β pathology, positioning it as a new therapeutic target.
Fei Qin, Runyu Cao, Xuemei Bai, Jiahua Yuan, Wanwei Sun, Yi Zheng, Xiaopeng Qi, Wei Zhao, Bingyu Liu, Chengjiang Gao   +9 more
wiley   +1 more source

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer

Advanced Science, EarlyView.
This study identifies a super‐enhancer‐driven transcriptional regulatory circuit comprising BCL6, SMAD3, and NFIB that cooperate to drive cholesterol synthesis via SREBF2/HMGCR/FDFT1 activation and regulate CDK2/CCND3 for cell cycle control. Targeting this circuit with BI‐3802 or downstream inhibitors (Fatostatin/Lovastatin) overcomes abiraterone ...
Liling Jiang, Jiamin Wang, Guanjie Peng, Haichuan Zhang, Jinxin Fang, Yingyin Gao, Enzhe Lou, Yangzhou Liu, Wa Ding, Bingyuan Liu, Qiong Mao, Lizhen Jiang, Aochu Liu, Xinyue Li, Shiwen Hu, Qiaomin Ma, Yueyuan Zheng, Zhigang Zhao, Xianping Shi   +18 more
wiley   +1 more source

Inhibiting FAT1 Blocks Metabolic Bypass to Enhance Antitumor Efficacy of TCA Cycle Inhibition through Suppressing CPT1A‐Dependent Fatty Acid Oxidation

Advanced Science, EarlyView.
This study demonstrates that mutant FAT1 promotes ASCL2‐driven, CPT1A‐dependent fatty acid oxidation, leading to resistance to CPI‐613‐mediated TCA cycle inhibition in head and neck cancer. In vivo gene depletion of mutant FAT1 with LNP‐sgFAT1 suppresses tumor growth and restores CPI‐613 sensitivity, revealing a targetable metabolic bypass with ...
Fanghui Chen, Jianqiang Yang, David O. Popoola, Fan Yang, Yajie Liu, Dongsheng Wang, Zhaohui S. Qin, Zhengjia Chen, Nabil F. Saba, Zhuo G. Chen, Yamin Li, Yong Teng   +11 more
wiley   +1 more source

Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity

Haematologica, 2008
Background c-Kit is expressed in the plasma cells from 30% of patients with multiple myeloma. Two different isoforms of c-Kit, characterized by the presence or absence of the tetrapeptide sequence GNNK in the extracellular domain, have been described ...
Juan Carlos Montero, Ricardo López-Pérez, Jesús F. San Miguel, Atanasio Pandiella   +3 more
doaj   +1 more source

Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding

Advanced Science, EarlyView.
The findings suggest that the combination of PIM‐2 and PARP1 inhibitors can induce MICA expression on MM cells, thereby activating NK cells through NKG2D binding. This process may restore NK cell function and serve as a potential therapeutic approach for MM patients. Abstract While immunogenic death in tumor cells activates specific anti‐tumor T cells,
Zhaoyun Liu, Wenhui Lei, Xiaohan Liu, Hui Liu, Kai Ding, Jia Song, Rong Fu   +6 more
wiley   +1 more source

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.

PLoS ONE, 2020
Cyclin Dependent Kinase 9 (CDK9) associates with Bromodomain and Extra-Terminal Domain (BET) proteins to promote transcriptional elongation by phosphorylation of serine 2 of RNAP II C-terminal domain.
Su-Lin Lim, Liang Xu, Bing-Chen Han, Pavithra Shyamsunder, Wee-Joo Chng, H Phillip Koeffler   +5 more
doaj   +1 more source

Mitochondrial Regulation of CD8⁺ T Cells: Mechanisms and Therapeutic Modulation

Advanced Science, EarlyView.
This article comprehensively explores the pivotal role of mitochondrial function in CD8⁺ T cell immunotherapy. It highlights how mitochondrial dynamics regulate T cell activation, differentiation, and persistence, and how mitochondrial dysfunction leads to immune exhaustion and impaired antitumor/antiviral responses.
Xu Chen, Pei Lin, Ye Lu, Jiarong Zheng, Yunfan Lin, Zihao Zhou, Li Cui, Xinyuan Zhao   +7 more
wiley   +1 more source

LncDARS‐AS1 Regulates ATP1A1 Stability and Enhances Na+/K+ ATPase Activity to Promote Osteosarcoma Metastasis

Advanced Science, EarlyView.
This study identifies LncDARS‐AS1 as a novel oncogenic regulator that stabilizes ATP1A1 and enhances Na⁺/K⁺ ATPase activity, promoting osteosarcoma metastasis. Targeting the LncDARS‐AS1/ATP1A1/NKA axis, including pharmacological inhibition with digoxin, offers promising opportunities for the development of new therapeutic strategies against ...
Mingxian Xu, Jiatian Wei, Xiaoyu Feng, Qinkai Zhang, Jian Chen, Xinyue Wang, Xiudan Zhan, Bing Lu, Weitang Guo, Mingzhe Cheng, Renxuan Huang, Shao Xu, Changye Zou   +12 more
wiley   +1 more source

Selective molecular inhibition of the HDAC6 ZnF-UBP binding domain impairs multiple myeloma cell function

Cell Death Discovery
Multiple myeloma is a plasma cell malignancy with a poor prognosis despite the recent development of new therapeutic options. Histone deacetylase 6 (HDAC6) is overexpressed in multiple myeloma cells and may be involved in the acquisition of resistance to
Rafael Rincón, Isabel F. Coira, Antoine Richieu, Fedaa Attana, Muriel Urwyler, Shozeb Haider, Carole Bourquin, Philippe Bertrand, Muriel Cuendet   +8 more
doaj   +1 more source

The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma

Haematologica, 2008
Background Azacitidine is a DNA methyltransferase inhibitor and cytotoxic agent known to induce apoptosis of some cancer cells. This study evaluated the pre-clinical potential of azacitidine as a therapeutic agent for multiple myeloma.Design and Methods ...
Tiffany Khong, Janelle Sharkey, Andrew Spencer   +2 more
doaj   +1 more source